This company listing is no longer active
Initiator Pharma Valuation
Is INIT BTA undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of INIT BTA when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate INIT BTA's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate INIT BTA's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for INIT BTA?
Other financial metrics that can be useful for relative valuation.
What is INIT BTA's n/a Ratio? | |
---|---|
n/a | 0x |
n/a | n/a |
Market Cap | DKK 249.89m |
Key Statistics | |
---|---|
Enterprise Value/Revenue | n/a |
Enterprise Value/EBITDA | -6.5x |
PEG Ratio | n/a |
Price to Book Ratio vs Peers
How does INIT BTA's PB Ratio compare to its peers?
Company | Forward PB | Estimated Growth | Market Cap |
---|---|---|---|
Peer Average | 1.9x | ||
MVIR Medivir | 1.9x | 35.0% | SEK 333.1m |
KAN Kancera | 2.9x | 77.1% | SEK 239.0m |
IMMU Mendus | 0.6x | 104.6% | SEK 413.4m |
SYNACT SynAct Pharma | 2.2x | n/a | SEK 406.8m |
INIT BTA Initiator Pharma | 12.9x | 21.5% | SEK 350.3m |
Price-To-Book vs Peers: INIT BTA is expensive based on its Price-To-Book Ratio (12.9x) compared to the peer average (1.7x).
Price to Earnings Ratio vs Industry
How does INIT BTA's PE Ratio compare vs other companies in the SE Biotechs Industry?
Price-To-Book vs Industry: INIT BTA is expensive based on its Price-To-Book Ratio (12.9x) compared to the Swedish Biotechs industry average (2.3x)
Price to Book Ratio vs Fair Ratio
What is INIT BTA's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
Fair Ratio | |
---|---|
Current PB Ratio | 12.9x |
Fair PB Ratio | n/a |
Price-To-Book vs Fair Ratio: Insufficient data to calculate INIT BTA's Price-To-Book Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.